Results 311 to 320 of about 143,566 (359)

Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experience. [PDF]

ESMO Open
Emiloju OE, Foster NR, Shah P, Opneja A, Gupta A, Singh M, Bonneau K, Steinert KO, Saeed A, Strickler JH, Overman MJ, Sinicrope FA.   +11 more
europepmc   +1 more source

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade

Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, Koji Haratani, Takayuki Takahama, Junko Tanizaki, Takeshi Yoshida, Tsutomu Iwasa, Kaoru Tanaka, Masayuki Takeda, T Hirano, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Kazuko Sakai, Keiko Higuchi, Hitoshi Uga, Chihiro Suminaka, Toyohiro Hirai, Kazuto Nishio, Kazuhiko Nakagawa, Tasuku Honjo   +28 more
openalex   +1 more source

Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models. [PDF]

Front Immunol
Tesfay MZ, Cios A, Ferdous KU, Shelton RS, Mustafa B, Simoes CC, Gokden M, Miousse IR, Krager KJ, Boerma M, Urbaniak A, Kunthur A, Obulareddy S, Eichhorn JM, Post SR, Chamcheu JC, Moaven O, Chabu CY, Duda DG, Conti M, Nardo B, Govindarajan R, Fernandez-Zapico ME, Roberts LR, Borad MJ, Cannon MJ, Basnakian AG, Nagalo BM.   +27 more
europepmc   +1 more source

Phenotypes of synovial fluid Treg cells in checkpoint blockade-related inflammatory arthritis. [PDF]

Front Oncol
He H, Zhou N, Wu K, Lin J, Zhou S, Gu Y, Wang X, Wang W, Mo L, Lv C.   +9 more
europepmc   +1 more source

IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity

Nilesh P. Talele, Heena Kumra, Igor L. Gomes‐Santos, William W. Ho, Patrik L. Andersson, Marie Siwicki, Peigen Huang, Dan G. Duda, Mikäel J. Pittet, Dai Fukumura, Rakesh K. Jain   +10 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immune Checkpoint Blockade

Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo, David B, Page, Jedd D, Wolchok   +2 more
openaire   +2 more sources

Masterful Antibodies: Checkpoint Blockade

Cancer Immunology Research, 2017
Abstract Cancer therapeutics that target the immune system rather than the cancer cell itself are becoming standard of care in a growing number of different malignancies. Although cancer immunotherapy is not a new concept, the potential importance of this class of drugs was probably not fully appreciated as recently as a decade ago when ...
Nils, Lonberg, Alan J, Korman
openaire   +2 more sources

Combined Immune Checkpoint Blockade

Seminars in Oncology, 2015
There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the ...
openaire   +2 more sources